Bejelentkezés Regisztrálj ingyen

4SC AG Bevétel Y / Y

Mi az 4SC AG Bevétel Y / Y?

A Bevétel Y / Y az 4SC AG - -7.80%

Mi a Bevétel Y / Y meghatározása?

Az elmúlt 3 évben az éves bevételnövekedés a bevételek növekedése az elmúlt 3 év átlagában az elmúlt 3 évben.

The yearly revenue growth rate is calculated as the percentage change in revenue over the trailing twelve months. For this specific metric, the calculation takes into account a series of the last eight quarterly revenues. The revenue growth is useful for determining the success of the company expanding its main business. Revenue growth of 5% to 10% is usually considered good for large-cap companies. For other companies, a sales growth of over 10% is more desirable.

Bevétel Y / Y a Health Care szektor a XETRA-on cégekben a 4SC AG -hoz képest

Mit csinál 4SC AG?

4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.

bevétel y / y -hoz hasonló cégek 4SC AG